A systematic review of the efficacy of ketamine for craniofacial pain

References

• Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, Steiner TJ, Zwart J-A. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193–17. doi:10.1111/j.1468-2982.2007.01288.x.
   PubMed Web of Science ®Google Scholar
• Ananthan S, Benoliel R. Chronic orofacial pain. J Neural Transm (Vienna). 2020 Apr;127(4):575–88. doi:10.1007/s00702-020-02157-3.
   PubMed Web of Science ®Google Scholar
• Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34. doi:10.1111/head.12482.
   PubMed Web of Science ®Google Scholar
• Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, Manack A, Proskorovsky I, Gladstone J, Buse DC, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011 Jul-Aug;51(7):1058–77. doi:10.1111/j.1526-4610.2011.01945.x.
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PRL, Nurmikko T, Obermann M, Cruccu G, Maarbjerg S. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 2020 Sep;19(9):784–96. doi:10.1016/S1474-4422(20)30233-7.
   PubMed Web of Science ®Google Scholar
• Chichorro JG, Porreca F, Sessle B. Mechanisms of craniofacial pain. Cephalalgia. 2017 Jun;37(7):613–26. doi:10.1177/0333102417704187.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Storer RJ, Park J-W, Goadsby PJ. N-Methyl-d-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats. Eur J Neurosci. 2019;50:2847–59. doi:10.1111/ejn.14423.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Baca SM, Akerman S. Neurovascular mechanisms of migraine and cluster headache. J Cereb Blood Flow Metab. 2019 Apr;39(4):573–94. doi:10.1177/0271678X17733655.
   PubMed Web of Science ®Google Scholar
• Cohen SP, Liao W, Gupta A, Plunkett A. Ketamine in pain management. Adv Psychosom Med. 2011;30:139–61.
   PubMed Web of Science ®Google Scholar
• Cohen SP, Bhatia A, Bhaskar A, Schwenk ES, Wasan AD, Hurley RW, Viscusi ER, Narouze S, Davis FN, Ritchie EC, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521–46. doi:10.1097/AAP.0000000000000808.
   PubMed Web of Science ®Google Scholar
• Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg. 2019;129:241–54. doi:10.1213/ANE.0000000000004185.
   PubMed Web of Science ®Google Scholar
• Adams HA. Mechanisms of action of ketamine. Anaesthesiol Reanim. 1998;23:60–63.
   PubMedGoogle Scholar
• Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997;86:903–17. doi:10.1097/00000542-199704000-00021.
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018 Jul;70(3):621–60. doi:10.1124/pr.117.015198.
   PubMed Web of Science ®Google Scholar
• Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1–211. doi:10.1177/0333102417738202.
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–58. doi:10.1016/S0304-3959(01)00349-9.
   PubMed Web of Science ®Google Scholar
• Covidence systematic review software, Veritas Health Innovation. Melbourne, Australia. www.covidence.org.
   Google Scholar
• Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Hernán MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919.
   PubMed Web of Science ®Google Scholar
• Moga C, Guo B, Schopflocher D, Harstall C. Development of a quality appraisal tool for case series using a modified Delphi technique. Edmonton (Canada): Institute of Health Economics; 2012.
   Google Scholar
• Rabben T, Skjelbred P, Oye I. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain. J Pharmaol Exp Ther. 1999;289:1060–66.
   PubMed Web of Science ®Google Scholar
• Benish T, Villalobos D, Love S, Casmaer M, Hunter CJ, Summers SM, April MD. The THINK (Treatment of headache with intranasal ketamine) trial: a randomized controlled trial comparing intranasal ketamine with intravenous metoclopramide. J Emerg Med. 2019 Mar;56(3):248–57. doi:10.1016/j.jemermed.2018.12.007.
   PubMed Web of Science ®Google Scholar
• Afridi SK, Giffin NJ, Kaube H, Goadsby PJ. A randomized controlled trial of intranasal ketamine in migraine with prolonged aura. Neurology. 2013;80:642–47. doi:10.1212/WNL.0b013e3182824e66.
   PubMed Web of Science ®Google Scholar
• Zitek T, Gates M, Pitotti C, Bartlett A, Patel J, Rahbar A, Forred W, Sontgerath JS, Clark JM. A comparison of headache treatment in the emergency department: prochlorperazine versus ketamine. Ann Emerg Med. 2018 Mar;71(3):369–77. doi:10.1016/j.annemergmed.2017.08.063.
   PubMed Web of Science ®Google Scholar
• Etchinson A, Bos L, Ray M, McAllister K, Mohammed M, Park B, Phan A, Heitz C. Low-dose ketamine does not improve migraine in the emergency department: a randomized placebo-controlled trial. West J Emerg Med. 2018 Nov;19(6):952–60. doi:10.5811/westjem.2018.8.37875.
   PubMed Web of Science ®Google Scholar
• Sarvari HR, Baigrezaii H, Nazarianpirdosti M, Meysami A, Safari-Faramani R. Comparison of the efficacy of intranasal ketamine versus intravenous ketorolac on acute non-traumatic headaches: a randomized double-blind clinical trial. Head Face Med. 2022 Jan 3;18(1):1. doi:10.1186/s13005-021-00303-0.
   PubMed Web of Science ®Google Scholar
• Rabben T, Øye I. Interindividual differences in the analgesic response to ketamine in chronic orofacial pain. Eur J Pain. 2001;5(3):233–40. doi:10.1053/eujp.2001.0232.
   PubMed Web of Science ®Google Scholar
• Mathisen LC, Skjelbred P, Skoglund LA, Oye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain. 1995 May;61(2):215–20. doi:10.1016/0304-3959(94)00170-J.
   PubMed Web of Science ®Google Scholar
• Granata L, Niebergall H, Langner R, Agosti R, Sakellaris L. Ketamin i. v. zur Behandlung von Clusterkopfschmerz: eine Beobachtungsstudie [Ketamine i. v. for the treatment of cluster headaches: an observational study]. Schmerz. 2016 Jun;30(3):286–88. German. doi:10.1007/s00482-016-0111-z. PMID: 27067225.
   PubMed Web of Science ®Google Scholar
• Petersen AS, Pedersen AS, Barloese MCJ, Holm P, Pedersen O, Jensen RH, Snoer AH. Intranasal ketamine for acute cluster headache attacks-results from a proof-of-concept open-label trial. Headache. 2022 Jan;62(1):26–35. doi:10.1111/head.14220.
   PubMed Web of Science ®Google Scholar
• Schwenk ES, Torjman MC, Moaddel R, Lovett J, Katz D, Denk W, Lauritsen C, Silberstein SD, Wainer IW. Ketamine for refractory chronic migraine: an observational pilot study and metabolite analysis. J Clin Pharmacol. 2021 Nov;61(11):1421–29. doi:10.1002/jcph.1920.
   PubMed Web of Science ®Google Scholar
• Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine infusions for treatment refractory headache. Headache. 2017;57:276–82. doi:10.1111/head.13013.
   PubMed Web of Science ®Google Scholar
• Schwenk ES, Dayan AC, Rangavajjula A, Torjman MC, Hernandez MG, Lauritsen CG, Silberstein SD, Young W, Viscusi ER. Ketamine for refractory headache: a retrospective analysis. Reg Anesth Pain Med. 2018 Nov;43(8):875–79. doi:10.1097/AAP.0000000000000827.
   PubMed Web of Science ®Google Scholar
• Ray JC, Cheng S, Tsan K, Hussain H, Stark RJ, Matharu MS. Intravenous lidocaine and ketamine infusions for headache disorders: a retrospective cohort study. Front Neurol. 2022 Mar;9(13):842082. doi:10.3389/fneur.2022.842082.
   Google Scholar
• Kaube H, Herzog J, Käufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 2000 Jul 12;55(1):139–41. doi:10.1212/wnl.55.1.139. PMID: 10891926.
   PubMed Web of Science ®Google Scholar
• Lauritsen C, Mazuera S, Lipton RB, Ashina S. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016 Dec;17(1):106. doi:10.1186/s10194-016-0700-3.
   PubMedGoogle Scholar
• Moisset X, Giraud P, Meunier E, Condé S, Périé M, Picard P, Pereira B, Ciampi de Andrade D, Clavelou P, Dallel R. Ketamine-magnesium for refractory chronic cluster headache: a case series. Headache. 2020 Nov;60(10):2537–43. doi:10.1111/head.14005.
   PubMed Web of Science ®Google Scholar
• Moisset X, Clavelou P, Lauxerois M, Dallel R, Picard P. Ketamine infusion combined with magnesium as a therapy for intractable chronic cluster headache: report of two cases. Headache. 2017 Sep;57(8):1261–64. doi:10.1111/head.13135.
   PubMed Web of Science ®Google Scholar
• Aggarwal A. Ketamine as a potential option in the treatment of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing. Natl Med J India. 2019 Mar-Apr;32(2):86–87. doi:10.4103/0970-258X.275347.
   PubMed Web of Science ®Google Scholar
• Shiiba S, Sago T, Kawabata K. Pain relief in short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome with intravenous ketamine: a case report. Acta Neurol Taiwan. 2021 Mar;30(1):35–38.
   Google Scholar
• Maher DP, Chen L, Mao J. Intravenous ketamine infusions for neuropathic pain management: a promising therapy in need of optimization. Anesth Analg. 2017;124:661–74. doi:10.1213/ANE.0000000000001787.
   PubMed Web of Science ®Google Scholar
• Ashina S, Olesen J, Lipton RB. How well does the ICHD 3 (Beta) help in real-life migraine diagnosis and management? Curr Pain Headache Rep. 2016 Dec;20(12):66. doi:10.1007/s11916-016-0599-z.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19. doi:10.1016/j.pain.2004.09.012.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB, American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017 Apr 1;74(4):399–405. doi:10.1001/jamapsychiatry.2017.0080.
   PubMed Web of Science ®Google Scholar
• Song B, Zhu JC. Mechanisms of the rapid effects of ketamine on depression and sleep disturbances: a narrative review. Front Pharmacol. 2021 Dec;14(12):782457. doi:10.3389/fphar.2021.782457.
   Google Scholar
• Chah N, Jones M, Milord S, Al-Eryani K, Enciso R. Efficacy of ketamine in the treatment of migraines and other unspecified primary headache disorders compared to placebo and other interventions: a systematic review. J Dent Anesth Pain Med. 2021 Oct;21(5):413–29. doi:10.17245/jdapm.2021.21.5.413.
   PubMedGoogle Scholar